Ignite Creation Date:
2024-07-17 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475755
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-28
Brief Title:
NeoadjuvantAdjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Sponsor:
Tang-Du Hospital
Organization:
Tang-Du Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Non-Small Cell Lung Cancer |
| Anti Angiogenesis |
Keywords: